What is Triamcinolone Ointment and how is it used?
Triamcinolone Ointment is a prescription medicine used to treat the symptoms of Topical Inflammatory Dermatoses and Oral Inflammatory or Ulcerative Lesions. Triamcinolone Ointment may be used alone or with other medications.
Triamcinolone Ointment belongs to a class of drugs called Corticosteroids, Topical.
What are the possible side effects of Triamcinolone Ointment?
Triamcinolone Ointment may cause serious side effects including:
- worsening of your skin condition,
- redness, warmth, swelling, oozing, or severe irritation of any treated skin,
- blurred vision,
- tunnel vision,
- eye pain,
- seeing halos around lights,
- increased thirst,
- increased urination,
- dry mouth,
- fruity breath odor,
- weight gain (especially in your face, upper back or torso),
- slow wound healing,
- thinning or discolored skin,
- increased body hair,
- muscle weakness,
- mood changes,
- menstrual changes, and
- sexual changes
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Triamcinolone Ointment include:
- burning, itching, dryness, or other irritation of treated skin,
- redness or crusting around your hair follicles,
- redness or itching around your mouth,
- allergic skin reaction,
- stretch marks,
- increased body hair growth,
- thinning skin or discoloration, and
- white or “pruned” appearance of the skin
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Triamcinolone Ointment. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Triamcinolone Acetonide (triamcinolone acetonide ointment) Ointment USP contains Triamcinolone Acetonide (triamcinolone acetonide ointment) [Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-, (11β,16α)-], with the molecular formula C24H31FO6 and molecular weight 434.50. CAS 76-25-5.
Triamcinolone Acetonide (triamcinolone acetonide ointment) Ointment USP, 0.025% contains: 0.25 mg of triamcinolone acetonide per gram in a base containing white petrolatum and mineral oil.
Triamcinolone Acetonide (triamcinolone acetonide ointment) Ointment USP, 0.1% contains: 1 mg triamcinolone acetonide per gram in a base containing white petrolatum and mineral oil.
3 pharmacies near 20147 have coupons for DermasilkRx SDS Pak (Brand Names:Triamcinolone Ointment for 15GM of 0.5%)
Est. Regular Price
with free coupon
Est. Regular Price
with free coupon
Est. Regular Price
with free coupon
DOSAGE AND ADMINISTRATION
Apply to the affected area as a thin film as follows: Triamcinolone Acetonide (triamcinolone acetonide ointment) Ointment USP, 0.025% two to four times daily; Triamcinolone Acetonide (triamcinolone acetonide ointment) Ointment USP, 0.1% two or three times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Triamcinolone Acetonide (triamcinolone acetonide ointment) Ointment USP, 0.025%
80 gram tubes.........NDC 0168-0005-80
Triamcinolone Acetonide (triamcinolone acetonide ointment) Ointment USP, 0.1%
15 gram tubes.........NDC 0168-0006-15
80 gram tubes.........NDC 0168-0006-80
1 Lb jars.................NDC 0168-0006-16
Store at controlled room temperature 15°-30°C (59°-86°F).
E. Fougera & CO. a division of Altana Inc., Melville, New York 11747.
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
No information provided.
No information provided.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steriod applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.
Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS-Pediatric Use). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate anti-fungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
The following tests may be helpful in evaluating the H PA axis suppression: Urinary free cortisol test; ACTH stimulation test.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.
Pregnancy Category C
Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced H PA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamicpituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to chil-dren should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.
Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Patients using topical corticosteroids should receive the following information and instructions.
- This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
- The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
- Patients should report any signs of local adverse reactions especially under occlusive dressing.
- Parents of pediatric patients should be advised not to use tight fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.